{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:42:23Z","timestamp":1772804543507,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T00:00:00Z","timestamp":1356048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00228-012-1449-5","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T12:58:29Z","timestamp":1356008309000},"page":"1285-1291","source":"Crossref","is-referenced-by-count":54,"title":["Influence of the UGT2B7 -161C&gt;T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients"],"prefix":"10.1007","volume":"69","author":[{"given":"Noppaket","family":"Singkham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somchai","family":"Towanabut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surang","family":"Lertkachatarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baralee","family":"Punyawudho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"key":"1449_CR1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45:1061\u20131075","journal-title":"Clin Pharmacokinet"},{"key":"1449_CR2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5414\/CPP47752","volume":"47","author":"JR Milovanovic","year":"2009","unstructured":"Milovanovic JR, Jankovic SM (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47:752\u2013760","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1449_CR3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","volume":"48","author":"B Punyawudho","year":"2008","unstructured":"Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK (2008) Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 48:455\u2013463","journal-title":"J Clin Pharmacol"},{"key":"1449_CR4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","volume":"30","author":"N Rivas","year":"2008","unstructured":"Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Dominguez-Gil A, Garcia MJ (2008) Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 30:483\u2013489","journal-title":"Ther Drug Monit"},{"key":"1449_CR5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","volume":"39","author":"TH Grasela","year":"1999","unstructured":"Grasela TH, Fiedler-Kelly J, Cox E, Womble GP, Risner ME, Chen C (1999) Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J Clin Pharmacol 39:373\u2013384","journal-title":"J Clin Pharmacol"},{"key":"1449_CR6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","volume":"43","author":"Z Hussein","year":"1997","unstructured":"Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43:457\u2013465","journal-title":"Br J Clin Pharmacol"},{"key":"1449_CR7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0300-483X(02)00449-3","volume":"181\u2013182","author":"JO Miners","year":"2002","unstructured":"Miners JO, McKinnon RA, Mackenzie PI (2002) Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181\u2013182:453\u2013456","journal-title":"Toxicology"},{"key":"1449_CR8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.104.002576","volume":"33","author":"A Mori","year":"2005","unstructured":"Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 33:672\u2013675","journal-title":"Drug Metab Dispos"},{"key":"1449_CR9","first-page":"73","volume":"26","author":"BL Coffman","year":"1998","unstructured":"Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73\u201377","journal-title":"Drug Metab Dispos"},{"key":"1449_CR10","first-page":"1","volume":"25","author":"BL Coffman","year":"1997","unstructured":"Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1\u20134","journal-title":"Drug Metab Dispos"},{"key":"1449_CR11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.clpt.6100324","volume":"83","author":"JY Chung","year":"2008","unstructured":"Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ (2008) Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther 83:595\u2013600","journal-title":"Clin Pharmacol Ther"},{"key":"1449_CR12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055\u20131062","journal-title":"Drug Metab Dispos"},{"key":"1449_CR13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/00008571-200011000-00002","volume":"10","author":"CR Bhasker","year":"2000","unstructured":"Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679\u2013685","journal-title":"Pharmacogenetics"},{"key":"1449_CR14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00008571-200011000-00007","volume":"10","author":"MB Fisher","year":"2000","unstructured":"Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, Wrighton SA (2000) Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics 10:727\u2013739","journal-title":"Pharmacogenetics"},{"key":"1449_CR15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/FPC.0b013e3283037fe4","volume":"18","author":"F Innocenti","year":"2008","unstructured":"Innocenti F, Liu W, Fackenthal D, Ramirez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ (2008) Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 18:683\u2013697","journal-title":"Pharmacogenet Genomics"},{"key":"1449_CR16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0090-9556(24)02990-8","volume":"32","author":"M Saeki","year":"2004","unstructured":"Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, Ueno K, Kamakura S, Kamatani N, Komamura K, Kitakaze M, Sawada J (2004) Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048\u20131054","journal-title":"Drug Metab Dispos"},{"key":"1449_CR17","doi-asserted-by":"crossref","unstructured":"Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95:1\u20138","DOI":"10.1016\/j.eplepsyres.2011.01.016"},{"key":"1449_CR18","doi-asserted-by":"crossref","unstructured":"Blanca Sanchez M, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM, Nicolas JM, Adin J, Shushtarian M, Armijo JA (2010) UGT2B7_-161C\u2009>\u2009T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study. Ther Drug Monit 32:177\u2013184","DOI":"10.1097\/FTD.0b013e3181ceecc6"},{"key":"1449_CR19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0920-1211(91)90012-5","volume":"10","author":"RE Ramsay","year":"1991","unstructured":"Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, Lai AA, Hubbell J, Chern WH, Allsup T et al (1991) Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 10:191\u2013200","journal-title":"Epilepsy Res"},{"key":"1449_CR20","unstructured":"Beal SL, Sheiner LB, Boeckmann AJE (1989\u20132006) NONMEM users guides. University of California, San Francisco"},{"key":"1449_CR21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO (1999) Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51\u201364","journal-title":"Comput Methods Programs Biomed"},{"key":"1449_CR22","doi-asserted-by":"crossref","first-page":"E523","DOI":"10.1208\/aapsj070353","volume":"7","author":"PR Jadhav","year":"2005","unstructured":"Jadhav PR, Gobburu JV (2005) A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J 7:E523\u2013E531","journal-title":"AAPS J"},{"key":"1449_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171\u2013192","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1449_CR24","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","volume":"23","author":"V Chan","year":"2001","unstructured":"Chan V, Morris RG, Ilett KF, Tett SE (2001) Population pharmacokinetics of lamotrigine. Ther Drug Monit 23:630\u2013635","journal-title":"Ther Drug Monit"},{"key":"1449_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","volume":"43","author":"PN Patsalos","year":"2002","unstructured":"Patsalos PN, Froscher W, Pisani F, van Rijn CM (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43:365\u2013385","journal-title":"Epilepsia"},{"key":"1449_CR26","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1528-1167.2007.00997.x","volume":"48","author":"J Christensen","year":"2007","unstructured":"Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, Sabers A (2007) Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 48:484\u2013489","journal-title":"Epilepsia"},{"key":"1449_CR27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF03191157","volume":"34","author":"M Lalic","year":"2009","unstructured":"Lalic M, Cvejic J, Popovic J, Bozic K, Golocorbin-Kon S, Al-Salami H, Mikov M (2009) Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. Eur J Drug Metab Pharmacokinet 34:93\u201399","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1449_CR28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/(SICI)1097-0258(19990315)18:5<581::AID-SIM47>3.0.CO;2-1","volume":"18","author":"A Yafune","year":"1999","unstructured":"Yafune A, Ishiguro M (1999) Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error. Stat Med 18:581\u2013599","journal-title":"Stat Med"},{"key":"1449_CR29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1177\/0091270003258670","volume":"43","author":"BP Booth","year":"2003","unstructured":"Booth BP, Gobburu JV (2003) Considerations in analyzing single-trough concentrations using mixed-effects modeling. J Clin Pharmacol 43:1307\u20131315","journal-title":"J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-012-1449-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1449-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:13:01Z","timestamp":1745464381000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-012-1449-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1007\/s00228-012-1449-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}